

## LABELLING

### PARTICULARS TO APPEAR ON THE OUTER PACKAGE

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ovipast Plus

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Per 1 ml:  $5 \times 10^8$  killed cells each of *M. haemolytica* strains A1, A2, A6, A7, A9\* and *P. trehalosi* strains T3, T4, T10, T15\*\*

\* inducing at least 22% OD reduction, measuring transferrin binding inhibition in rabbit sera

\*\* inducing a significant ( $p < 0.05$ ) OD increase, determining antibody response in rabbit sera

Aluminium hydroxide gel, Thiomersal

**3. PHARMACEUTICAL FORM**

Suspension for injection

**4. PACKAGE SIZE**

100 ml, 500ml

**5. TARGET SPECIES**

Sheep

**6. INDICATION(S)**

Vaccine against pasteurellosis caused by *M. haemolytica* and *P. trehalosi*

**7. METHOD AND ROUTE OF ADMINISTRATION**

s.c. injection of 2 ml

Read package leaflet before use

**8. WITHDRAWAL PERIOD**

Withdrawal period: Zero days

**9. EXPIRY DATE**

EXP:

Once broached use within 10 hours

**10. SPECIAL STORAGE CONDITIONS**

Store at 2°C to 8°C in the dark. Do not freeze.

**11. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only

**12. THE WORDS "KEEP OUT OF THE REACH AND SIGHT OF CHILDREN"**

Keep out of the reach and sight of children

**13. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
Netherlands

Distributor in Northern Ireland:  
Intervet Ireland Ltd.  
Magna Drive,  
Magna Business Park,  
Citywest Road,  
Dublin 24

**14. MARKETING AUTHORISATION NUMBER**

Vm 06376/4118

**15. MANUFACTURER'S BATCH NUMBER**

Lot:

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ovipast Plus

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Per 1 ml:  $5 \times 10^8$  killed cells each of *M. haemolytica* strains A1, A2, A6, A7, A9\* and *P. trehalosi* strains T3, T4, T10, T15\*\*

\* inducing at least 22% OD reduction, measuring transferrin binding inhibition in rabbit sera

\*\* inducing a significant ( $p < 0.05$ ) OD increase, determining antibody response in rabbit sera

**3. PHARMACEUTICAL FORM**

Suspension for injection

**4. PACKAGE SIZE**

100 ml, 500ml

**5. TARGET SPECIES**

Sheep

**6. ROUTE OF ADMINISTRATION**

s.c. injection of 2ml

Read package leaflet before use

**7. WITHDRAWAL PERIOD**

Withdrawal period: zero days

**8. EXPIRY DATE**

EXP: .....

Once broached use within 10 hours

**9. SPECIAL STORAGE CONDITIONS**

Store at 2°C to 8°C in the dark. Do not freeze.

**10. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only

**11. NAME OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
Netherlands

**12. MANUFACTURER'S BATCH NUMBER**

Lot. ....

## PACKAGE LEAFLET

Ovipast Plus

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing Authorisation Holder:

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
Netherlands

Manufacturer responsible for batch release<sup>1</sup>:

Intervet International BV  
Wim de Körverstraat 35  
5831 AN Boxmeer  
The Netherlands

MSD Animal Health UK Ltd.  
Walton Manor, Walton, Milton Keynes  
Buckinghamshire, MK7 7AJ  
United Kingdom

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ovipast Plus

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Per 1 ml:

5 x 10<sup>8</sup> formalin killed cells each of *M. haemolytica* strains A1 (S1006/77), A2 (S1126/92), A6 (S1084/81), A7 (S1078/81), A9 (S994/77), inducing at least 22% OD reduction, measuring transferrin binding inhibition in rabbit sera;

5 x 10<sup>8</sup> formalin killed cells each of *P. trehalosi* strains T3 (S1109/84), T4 (S1085/81), T10 (S1075/81), T15 (S1105/84), inducing a significant (p<0.05) OD increase, determining antibody response in rabbit sera.

Aluminium hydroxide gel, Thiomersal

### 4. INDICATION(S)

For active the immunisation of sheep as an aid in the control of pasteurellosis caused by *M. haemolytica* and *P. trehalosi*. The vaccine maybe used as an aid in the control of pneumonic pasteurellosis in sheep of all ages from a minimum age of 3 weeks and in the control of systemic pasteurellosis in weaned fattening and breeding sheep.

---

<sup>1</sup> The printed package leaflet will state the name and address of the manufacturer responsible for the release of the concerned batch only.

The vaccine may be used in pregnant ewes as an aid in the control of pasteurellosis in their lambs provided that the lambs receive sufficient immune colostrum during the first 1-2 days of life.

## **5. CONTRAINDICATIONS**

None

## **6. ADVERSE REACTIONS**

The vaccine contains an adjuvant and, as with most adjuvanted vaccines, immunisation may result in temporary swellings at the injection site. Typically, these swellings may be warm when compared to the surrounding area for up to 14 days after vaccination. Safety studies in lambs have shown that the swellings did not appear to inconvenience the animals or hinder neck movement.

As with all vaccines, occasional hypersensitivity reactions may occur.

## **7. TARGET SPECIES**

Sheep

## **8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION**

Subcutaneous injection in the lateral side of the upper neck

All sheep not previously vaccinated with Ovipast Plus must receive two injections, each of 2.0ml, separated by an interval of 4-6 weeks. Thereafter they must receive booster injections at intervals of not more than 12 months.

In adult breeding ewes these yearly booster injections should be given during the pre-lambing period, 4-6 weeks pre-lambing, as an aid in the control of pasteurellosis in their lambs.

On farms where the incidence of pasteurellosis is high, a supplementary booster vaccination with Ovipast Plus may be required 2-3 weeks prior to expected seasonal outbreaks.

## **9. ADVICE ON CORRECT ADMINISTRATION**

When handling sheep, stress should be avoided, particularly during the later stages of pregnancy when there is a risk of inducing metabolic disorders which may lead to abortion.

The vaccine bottle must be shaken well before use. Do not freeze.

Use sterile syringes and needles. No alcohol or other disinfectants should be used for sterilisation.

The use of an automatic vaccinator is recommended. Since the bottle is non-collapsible, a vaccinator with a vented draw-off spike or similar device must be used. The instructions supplied with such equipment should be noted and care should be taken to ensure the delivery of the full dose, particularly with the final few doses from the bottle.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be

made on a case by case basis.  
Do not mix with any other veterinary medicinal product.

#### **10. WITHDRAWAL PERIOD**

Zero days

#### **11. SPECIAL STORAGE PRECAUTIONS**

Store at +2°C - +8°C in the dark. Do not freeze.  
Once broached use within 10 hours

#### **12. SPECIAL WARNING(S)**

The nutritional and metabolic status of pregnant ewes is extremely important at the time of vaccination. If in doubt, advice should be sought from a veterinary surgeon.

#### **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS , IF ANY**

Partly used and empty packs, syringes and needles must be disposed of in accordance with the requirements for clinical waste.

#### **14. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

#### **15. OTHER INFORMATION**

In any group of animals, a small number of individuals may fail to respond to vaccination as a result of immunological incompetence. Satisfactory immune responses will only be attained in healthy animals, thus it is important to avoid vaccination of animals which have intercurrent infection or metabolic disorder. As with most killed vaccines, significant levels of immunity cannot be expected until two weeks after the second dose vaccine in the primary vaccination course. Evidence of efficacy of the Pasteurella/Mannheimia component of Heptavac P Plus was generated in an experimental infection model and it is not possible to provide duration of immunity information using this system. There are reports that active immunity will last for up to one year and that passive immunity will persist for up to 4 weeks after birth in lambs from ewes vaccinated with conventional Pasteurella vaccines.

Heptavac P Plus, Ovivac P Plus and Ovipast Plus have been developed following research and development which resulted in the application of new

'IRP' technology for the manufacture of the Pasteurella/Mannheimia components of these vaccines. The inclusion of these IRP components should provide enhanced efficacy and cross protection e.g. protection against serotype A12, which is not included in the vaccine, has been demonstrated. Studies on the response of sheep to these vaccines show that two injections separated by an interval of 4-6 weeks are required to gain the full benefit of the 'IRP'.

For animal treatment only.

Pack sizes: 100 or 500 ml.  
Not all pack sizes may be marketed.

Keep out of the reach and sight of children

**Marketing Authorisation number:**

Vm 06376/4118

**Legal category**

**POM-VPS**

To be supplied only on veterinary prescription

Distributor in Northern Ireland:  
Intervet Ireland Ltd.  
Magna Drive  
Magna Business Park  
Citywest Road  
Dublin 24

Approved 18 November 2024  
*Gavin Hall*